Drug Profile
ORG 43228
Latest Information Update: 20 Oct 2009
Price :
$50
*
At a glance
- Originator Organon
- Class
- Mechanism of Action Selective estrogen receptor alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Menopausal syndrome
Most Recent Events
- 20 Oct 2009 Discontinued - Phase-I for Menopausal syndrome in USA (unspecified route)
- 19 Nov 2007 Organon has been acquired by Schering-Plough
- 02 Jun 2006 Phase-I clinical trials in Gynaecological disorders in USA (unspecified route)